Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 14,134 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Anal Fistula, Complex Perianal Fistula
Interventions: RhPDGF-BB; Drug
Lead sponsor: Alexander Hawkins; Other
Eligibility: 22 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Breastfeeding, Exclusive, Pain, Acute, Maternal Distress, Parent-Child Relations, Self Efficacy
Interventions: The BSM Intervention, Attention Control; Behavioral
Lead sponsor: University of Connecticut; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Farmington, Connecticut • Hartford, Connecticut

Conditions: Peanut Allergy
Interventions: HAL-MPE1, HAL-MPE1 placebo; Biological · Drug
Lead sponsor: HAL Allergy; Industry
Eligibility: 5 Years to 50 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 6
States / cities: Baltimore, Maryland • New York, New York • Chapel Hill, North Carolina + 3 more

Conditions: Gastroenteritis Escherichia Coli
Interventions: Ciprofloxacin, Peru-15-pCTB, Sodium bicarbonate/Ascorbic Acid/Aspartame Buffer; Drug · Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Diabetes Mellitus, Type 2
Interventions: CS-917, metformin hydrochloride, pioglitazone; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 66
States / cities: Birmingham, Alabama • Northport, Alabama • Mesa, Arizona + 62 more

Conditions: Obesity, Inflammation
Interventions: Yogurt, Control food; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 21 Years to 55 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Epilepsy
Interventions: Brivaracetam, Lorazepam; Drug
Lead sponsor: UCB Biopharma S.P.R.L.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 14
States / cities: Birmingham, Alabama • Tucson, Arizona • Orlando, Florida + 10 more

Conditions: Graft Versus Host Disease
Interventions: Prochymal®, Placebo, Corticosteroid; Drug · Other
Lead sponsor: Mesoblast, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 45
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 30 more

Conditions: Contraception
Interventions: ESS505 (BAY1454033); Device
Lead sponsor: Bayer; Industry
Eligibility: 21 Years to 44 Years · Female only
Enrollment: 660 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2024
U.S. locations: 17
States / cities: Aurora, Colorado • Denver, Colorado • Wellington, Florida + 14 more

Conditions: Acute Ischemic Stroke From Large Vessel Occlusion
Interventions: ANA Funnel Catheter, Control; Device
Lead sponsor: Anaconda Biomed S.L.; Industry
Eligibility: 22 Years to 85 Years
Enrollment: 327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 11
States / cities: Jacksonville, Florida • Atlanta, Georgia • Park Ridge, Illinois + 8 more

Conditions: Type 2 Diabetes
Interventions: 2S, 4R Ketoconazole (DIO-902); Drug
Lead sponsor: DiObex; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 5
States / cities: Washington D.C., District of Columbia • Omaha, Nebraska • Portland, Oregon + 2 more

Conditions: Laparoscopic Cholecystectomy, Pain
Interventions: placebo, valdecoxib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 490 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 65
States / cities: Birmingham, Alabama • Daphne, Alabama • Fairhope, Alabama + 47 more

Conditions: Atopic Dermatitis
Interventions: DS107, Placebo; Drug
Lead sponsor: DS Biopharma; Industry
Eligibility: 18 Years and older
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 26
States / cities: Birmingham, Alabama • Huntington Beach, California • Los Angeles, California + 22 more

Conditions: Tinea Corporis
Interventions: Naftin Cream, Placebo Cream; Drug
Lead sponsor: Merz North America, Inc.; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 230 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 14
States / cities: Tucson, Arizona • Encino, California • Fremont, California + 10 more

Conditions: Acne
Interventions: Acne mRNA vaccine, Placebo; Biological · Other
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 79
States / cities: Scottsdale, Arizona • Cerritos, California • Encino, California + 64 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Olodaterol (BI1744), placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 625 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 21
States / cities: Jasper, Alabama • Berkeley, California • Los Angeles, California + 17 more

Conditions: Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Interventions: Mosunetuzumab, Tocilizumab, Venetoclax, Rituximab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 5
States / cities: Rochester, Minnesota • New York, New York • Columbus, Ohio + 2 more

Conditions: Acute Heart Failure With Reduced Ejection Fraction
Interventions: APD418, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 5
States / cities: Tampa, Florida • Peoria, Illinois • Houston, Texas + 2 more

Conditions: Hereditary Inclusion Body Myopathy (HIBM), GNE Myopathy
Interventions: ManNAc; Drug
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Irritable Bowel Syndrome, Abdominal Pain
Interventions: Social Learning and Cognitive Behavioral Therapy (SLCBT), Attention Education Control; Behavioral
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hypercholesterolemia
Interventions: REGN727(SAR236553); Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Cincinnati, Ohio • Knoxville, Tennessee

Conditions: Migraine Without Aura, Migraine With Aura
Interventions: Nerivio Migra-1 active device, Nerivio Migra-1 Sham device; Device
Lead sponsor: Theranica; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 7
States / cities: Hartford, Connecticut • Springfield, Missouri • St Louis, Missouri + 4 more

Conditions: Thyroid Lobectomy
Interventions: Pre-Surgery Survey, Post-Surgery Surveys; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET
Interventions: RYZ101, Everolimus, Sunitinib, Octreotide, Lanreotide; Drug
Lead sponsor: RayzeBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 32
States / cities: Phoenix, Arizona • Duarte, California • Irvine, California + 27 more

Search by objective public record fields.

Evaluating an rhPDGF-BB-enhanced Collagen Plug for Perianal Fistula Healing

Promoting Self-Management of Breast and Nipple Pain With Technology (PROMPT) for Breastfeeding Women Study

HAL-MPE1 Safety and Tolerability Study

Safety and Immunogenicity of Peru-15-pCTB in Healthy Adult Subjects

Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917

Yogurt for Prevention of Chronic Inflammation

A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting

Efficacy and Safety of Prochymal® Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute Graft Versus Host Disease (GVHD)

Evaluation of Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in Women

Safety and Effectiveness of Mechanical Thrombectomy Using the Anaconda ANA Funnel Catheter

A Phase 1/2a Study of the 2S,4R Enantiomer of Ketoconazole in Subjects With Type 2 Diabetes Mellitus

A Randomized, Double-Blind Study of the Efficacy and Safety of Valdecoxib Compared to Placebo for Treatment of Post- Cholecystectomy Surgery Pain

Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis

Pediatric Subjects With Tinea Corporis

Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne

12 / 48 Week Pivotal PFT vs PBO in COPD I

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

A Study to Assess the Hemodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Intravenous APD418 in Adult Participants With Heart Failure With Reduced Ejection Fraction

Phase I Clinical Trial of ManNAc in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)

Online Social Learning Program for Parents With Irritable Bowel Syndrome: Raising Resilient Children

Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant Atorvastatin

Evaluation of a Novel Device for Treatment of Migraine Headache

A Randomized Control Trial for Patient Reported Outcomes and Safety in Outpatient Thyroid Lobectomy

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy